Clinical trial · Observational
Clinical-immunological Features of DNER Ataxia
NCT05225896CI-TRIAL-00056345CLIMDAunknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Using a retrospective cohort of 34 patients with DNER ataxia, we will characterize clinical presentation, tumor associations, and outcomes.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| DNER Ataxia | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Description of clinical characteristic and genetic tumors | Genetic | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- label
- DNER ataxia
- description
- Patients with well-characterized DNER antibodies.
- interventionNames
- Genetic: Description of clinical characteristic and genetic tumors
Primary outcomes (1)
- measure
- Modified Rankin scale (mRS)
- timeFrame
- 6 month after the beginning of study
- description
- Residual neurological disability as assessed by the modified Rankin scale (mRS) score at last visit)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patient \> 18 years old * Patient with neurological disorder * Patient with DNER antibodies in sera or CSF Exclusion Criteria: * \- No available clinical data * Patient without DNER antibodies or neurological disorder
References
Publications (0)
Data not yet available
No reference posted for this study.